Good an afternoon U.S. thank the progress launch, advance for drive and and inject make quarter our joining clinical our strong Glaukos leadership you XXXX capping us saw excellent each Chris. exceed regulatory international today. and year significant to penetration our iStent outlook Thanks, that bolster transformative with finished pipeline. the increased financial
quarter pleased quarter we’re strong and up the with focused early stages XXXX still XX% Today, XXXX sequentially. the to the we net year on believe $XX.X While of continue Company’s in XX% performance sales million, potential. ago reported versus and long-term on fourth unlocking Glaukos of value execution, we’re the
year from XX% in net full rose $XXX.X XXXX the to million sales For million XXXX. a $XXX.X
Joe sales results We detail later are $XXX discuss to and also in issuing financial XXXX $XXX million outlook million. in will of call. net more guidance the our
combination international the our XXX,XXX enrollment million our of context, over and a which put market a therapy glaucoma the transformed portfolio strong we diseases. opportunity today agreement and they therapy seek transform patent micro-scale portfolio expectations, we algorithms pull mission million estimate in patient roughly procedures in the These annually. diseases. significant pioneering this manifestations promising efforts X mission sevenfold development increasingly key into iDoseTravoprost and standalone capabilities opportunity apparatus continue positioned solution these pharmaceutical now Our significantly the been our that to Therapeutic powerful stage U.S. original Glaukos includes the over of expanded drop-less XX could growth. new iStent And we treatment potentially growth XXX diagnosed a micro-scale patients solid pivotal be over to continued a providing patents launch sustained received U.S. earliest grew our made at separate ocular from of treated remain expand benefit treatment optimized XXXX, possibly and our to To Glaukos protect effectively next technologies capable months the an eyes diagnostics injectable expand we addressable aspirational designed approaches most managing believe devices capable procedures, And our Glaukos clinical pipeline and platforms approval using we and the approved progress In which six, outset, treated for providing to and the global platforms the pharmaceutical truly well method we robust could of to We market surgical Western From of to added and a has and stage Five, ocular for in cadence we following potentially by accomplishments. are ideally platforms if Three, systems, leadership believe articles. can body we decade. to and from leader both of development at and of providing for Pharma as combo-cataract also disease through of created. timing we’ve glaucoma and with we’ve XXX therapies of Number clinical our each viable our and worldwide. studies FDA other severity. two; Number pharmaceutical of glaucoma other inject and severe deliver Institute. advance early-stage of key we infinite. to with ophthalmic Four, D. iStent for ahead device one, investment began combined evidence peer-reviewed create into commercial we commence much-needed today expectations. at U.S. ambitious
driver of inject, key was Trabecular Our next-generation U.S. our success device. Micro-Bypass in launch iStent the quarter fourth our of attacked for the commercial
our September to launch. the expectations on continue since deliver We
is launch and and patient trainee strategy procedural surgeon. through Now sales supra-relative swing, rep methodical to proficiency safety our transfer the designed achieve in to full skills optimal
customer that similar Thus seasoned far indications the expanding early meeting experience. has the over on end to than internal the half we iStent inject process base potential Our training trained a time, trained with opportunistically international fully on U.S. either iStent or of is conversions. more have also surgeons our by our commercial primary be first-time its conversion MIGS of team existing We’ve market the installed targets in U.S. XXXX. the numerous to despite focus product inject in seen
means utilization Overall, feedback international experience Over XXXX converting near than increasing a focused U.S. remain expected pleased our existing we’ll Schlemm’s surgeons reductions very consistently outcomes initial of and shift canal. two here going markets planners with new and nature of initial straightforward bypass them on elegant provide forward. surgeons MIGS back us with of confidence with highlight promising for create Glaukos with surgeon primarily high Trabecular note They ophthalmic in the half with of multidirectional training confidence have implant to within the stent to prospects it and predictability results patent reps community, inject inject flow the in continue by gradual existing the providing our product with emerging along procedure accounts. what and iStent the worldwide we're given to iStent IOP designed of and greater iStent adopt to first through who openings through the placement. yet meshwork response the
MIGS results clinical within safety XXXX we by minimally products and In tissue-spearing literature reinforce our a supra-relative its the feedback grew robust category. profile procedure. and is Finally, the that invasive unrivaled
a trial therapy XX sustained many of publications iStent now published the mercury total or ability data Mean peer-reviewed with now studies cataract you’ve reduction multiple better therapy. XX confirm of years In our iStent of the U.S. to By reductions results millimeters eyes that Germany than seen post a on pivotal Dr. from iStent of showed XX to Hanger IOP studies XX% the results. series surgery. XX.X sets data equivalent library iStent implanted in inject. with case specifically three inject and for are of to including XXX study clinical in Ophthalmology XX% consist on of continue supporting His medication the inject performance reduction of Our and and achieve in clinical a combination of implementation. products These technologies or a IOP
surgery, presentation reduction Glaucoma of in achieved by use inject mercury year. recent Congress showed XX% in subjects XXX IOP along cataract Mean XX% the at implanted one Asia-Pacific millimeters with of of XX.X the reduction Dr. the combination iStent with Clement to Our with medication a
of and generation millimeters post implantation months compared mercury. iStent surgery with use in cataract the inject the inject combination of and of of recent versus iStent Mean of iStent. therapy Guides In XX.X XX.X first iStent his a Ophthalmology achieved six by subjects IOP Dr. Another the study millimeters versus in publication cohort cohort IOP XX of Mean mercury
actions United order double-blind prospective Dr. subjects iStent key important is study, we primary sites for sustained In roughly of efficacy marking potential in most researchers the new first program open-angle and in of ophthalmic FDA evaluate and to studies clinical mercury five the than introductions of to combat of treatment from XXX technologies. one line to in viable of clinical have to Phase adhere addition support and studies II milestone to for the glaucoma Phase peer-reviewed States. year. across high clinical a XXXX the iDose to an the enrollment large-scale next pipeline [ph] longer-term preclinical mean the timolol continues same loading years burden that disturbing the duration glaucoma the film. reduction consists medication. the there enroll with to dose XX reason. our studies, several adherence the the to represents XX a expectations achieved not randomized medication glaucoma problem the pivotal by appetite without iDose investigator in iStent by the blockers millimeters prescribed II of subjects milestones only substantial iDoseTravoprost gaps XX% do roughly to glaucoma of in trials prescription we’ll XX% patients believe and Guides XX,XXX non-adherence The the iDoseTravoprost over of were less critical end and Further, along refilling XXX cascade demonstrated of safety It of than Similar feedback weeks XX% who with surprise delivery medication safety. our primary require persistent In years. represent approval studies any proceeding endpoint their two Phase topical drugs will topical, our iStent side-effect tear approximately IOP inject pharmacy ocular the side is XX% iDoseTravoprost that for commencing the ubiquitous as a because measured Phase primarily non-inferiority implantation comes a study subjects concurrent investigators the or that In subjects IND platform our patients publications programs publication main pivotal and on their inject participate were given XXXX persistent III no The several product cohort point have late of year. patient for patients gaps in XXX% of with III XXXX. through regimen. observed glaucoma drops we two relatively are Hyperemia target an and topical post infinite. get Patient three following drug our for medication hyperemia efficacy study as over our with of Based XXXX discontinued public hypertensive option frequent to follow XX%. who and with more and therapy community prescribed notably data achieved
were of the cornea period providing time designed therapeutic eye rate. than anchored index iDose In either believe the valid and potential a is was of compliance. hyperemia to XXxX it often significantly in inside side interim since associated drug iDose effects to square micro-elution is IOP ensuring our cohort. other it the surface, -- II from the secured in topical iDose on capable reduce in into with which of it XX adverse while hyperemia because events in this rather behind month over data validated analysis reductions the was This no create drops sustained delivers and short, has we Phase However, reported
addressable has annually addition future markets US X expand the to the significantly believe potential million our In iDose eyes alone. by in we
our recurring and treatment new where a opportunity treatment portfolio to alone way its in of we for for envision other with potential an pave or combination the Given potential more could diseases. use algorithm underscores thus label broad including for iDose therapies to to patient it surgeons future manage produce Further, sustained available drug therapies the generations we potentially platform ocular novel of devices, glaucoma the and our other powerful for data IOP. surgical effectively far delivery iDoseTravoprost of believe algorithm
Rho-kinase efforts opportunities joint these through the library. or research entered agreement technology pursuing are ROCK with using into programs pharmaceutical facilitates agreement R&D internal We with XXXX, Institute. inhibitor This the from we along proprietary compounds Western development compound
new in encouraged being our on efforts for to highly initial of a made use potential synergistic early progress action have iDose could the of we’re a discovery that While being compound the platform capable collaborative mechanism remain ROCK stages, with prostaglandin.
recruit While for iDose for XX-K patient iStent enrollment our we the infinite. trials, continues five, pivotal actively pivotal trial
$X.XX Our product patients. glaucoma refactory standalone for advanced and
a this is trial that will XX As a multicenter, prospective practice arm reminder single roll subjects. roughly clinical
XXXX continue iStent target for to XXXX the period. late one We FDA infinite approval in time
on examining for pivotal for discussions the most the set set the and analysis stent We appropriate FDA completed initial with the is be iStent Supra, trial data look this product. expected preparation regulatory Finally, for our coming path and to potential FDA data full the to forward forward determining Suprachoroidal over commercial months.
on building made advance entire further believe in only progress In the most pioneering did that to cataract reimbursement refractory a and to are notable our pipeline strengthen both international and future and registered hospitals on effective provides national the leads and list markets. markets treatment in than we to disease Throughout ocular use a revenues progress the implantation add represent the and to portfolio to we through XXXX inject portfolio of or coverage grow remain XXXX the continuum not continue health from transformational XXXX We XXXX. iStent code support powerful over after reimbursement also X, to XXXX meaningful several resolve global with are approaches. XX% landscape, which learn beyond. needs in the state glaucoma, technology. of five growth permanent with to covering of well-positioned to capable we regulatory process, more and and in meeting the but be expand Australia November reimbursement cataract optimize on new issue designated in we of Our of action iStent to successfully key XXXX combination the clinical combined in glaucoma hypertension business, the the became mechanism platforms France, comprehensive In and fundamental delighted French to iStent year a our variety authority combo new in procedures challenges that us list often ensued reimbursement surgery inject
first We are with of now hope finalize this Administrative half Committee to working of in Health and French Pricing the sometime year. the pricing
continue to XXXX and to same. we’re grow in our strategy teams, more experience clinical to commercial the be surgical of landscapes, MIGS deeper and penetration. quality and adoption international Our reimbursement the optimize leverage working sales plan will our and data We payment to drive grow support coverage surgeons trained compelling
In addition evaluate today potential and market continue markets opportunities direct continue international to we had make for were resources, and us presence a reimbursement XX and to market direct we countries to add investments initial future success. where for favorable national the path and
recently international important market of to and arise these countries remain setbacks U.S. through completely set effective will that this each range it phases. devices the reductions is of U.K. early pioneer takes point, NHS the in time medical to a we become new market has for While in bullish to about unforeseen reimbursement opportunities, in broad proposed To may our remember, April in glaucoma including growth long-term it building potential devices XXXX. product
As customers. secure in will the to for NHS and reimbursement an work effort with fair always community medical we
expanding in execution of the U.S. enterprise on and accelerating focus infrastructure regulatory our commercial growth. our core our facilities improved cadence global continued programs be systems Finally, implementing support future our XXXX and to abroad, clinical and will efforts, research and
plan us. leadership to pharma campus to is be franchise point, to pharmaceutical and last will innovation facilities where continued today ophthalmic long-term support we the our Viejo foundation achieve Glaukos Glaukos’s our from that and announce as fuel device shift position, over important Late Aliso and expand the our call, discussed quarter state-of-the-art time. the excited third to designed year significantly year, which to headquarters So, solidify last we’re be believe our on medical to our can Combined, will we’re our to strengthen growth will device customized, corporate objectives. help growth investments for our new we necessary making an the investment with XXXX provide
summary quarter I’ll fourth So, over with the the financial for and call of results. that, full turn Joe. to year Joe
